We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
-9.26%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$321M
AUM Growth
-$44.2M
Cap. Flow
+$330K
Cap. Flow %
0.1%
Top 10 Hldgs %
50.52%
Holding
83
New
10
Increased
22
Reduced
13
Closed
8

Top Buys

Rank Stock Value
1
TSVT
2seventy bio
TSVT
+$6.24M
2
CYTK icon
Cytokinetics
CYTK
+$4.89M
3
AXGN icon
Axogen
AXGN
+$4.18M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$3.04M
5
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$2.59M

Top Sells

Rank Stock Value
1
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$24.1M
2
SAGE
Sage Therapeutics
SAGE
+$8.48M
3
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$5.93M
4
LYRA
LYRA THERAPEUTICS INC
LYRA
+$1.48M
5
RVMD icon
Revolution Medicines
RVMD
+$1.15M

Sector Composition

Rank Sector Weight
1 Healthcare 82.12%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MGNX icon
51
MacroGenics
MGNX
$255M
$1.2M 0.37%
+258,496
New +$1.29M
CGEM icon
52
Cullinan Oncology
CGEM
$1.16B
$1.15M 0.36%
+127,284
New +$1.33M
ACET icon
53
Adicet Bio
ACET
$74.2M
$1.09M 0.34%
49,816
– –
ITOS
54
DELISTED
iTeos Therapeutics
ITOS
$1.08M 0.34%
98,560
– –
SYRS
55
DELISTED
Syros Pharmaceuticals, Inc. Common Stock
SYRS
$1.05M 0.33%
265,878
– –
STRO icon
56
Sutro Biopharma
STRO
$400M
$982K 0.31%
28,308
+4,030
+17% +$176K
MRSN
57
DELISTED
Mersana Therapeutics
MRSN
$932K 0.29%
29,362
-3,072
-9% -$146K
VIGL
58
DELISTED
Vigil Neuroscience
VIGL
$929K 0.29%
172,308
– –
BHVN icon
59
Biohaven
BHVN
$2.17B
$910K 0.28%
35,000
+13,887
+66% +$289K
IMVT icon
60
Immunovant
IMVT
$8.21B
$864K 0.27%
+22,500
New +$509K
ACRV icon
61
Acrivon Therapeutics
ACRV
$72.3M
$735K 0.23%
76,852
– –
NVRO
62
DELISTED
NEVRO CORP.
NVRO
$538K 0.17%
28,000
– –
STIM icon
63
Neuronetics
STIM
$157M
$424K 0.13%
313,717
– –
ELEV
64
DELISTED
Elevation Oncology
ELEV
$298K 0.09%
450,000
– –
ADAP
65
DELISTED
Adaptimmune Therapeutics
ADAP
$274K 0.09%
351,064
– –
MASI
66
DELISTED
Masimo
MASI
$263K 0.08%
3,000
– –
KPTI icon
67
Karyopharm Therapeutics
KPTI
$44.2M
$258K 0.08%
12,845
– –
CMPX icon
68
Compass Therapeutics
CMPX
$358M
$230K 0.07%
116,882
– –
NXTC icon
69
NextCure
NXTC
$22.7M
$214K 0.07%
13,849
-1,792
-11% -$34.2K
CGEN icon
70
Compugen
CGEN
$218M
$191K 0.06%
205,202
– –
SPRO icon
71
Spero Therapeutics
SPRO
$73.5M
$151K 0.05%
125,000
– –
KNTE
72
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
$147K 0.05%
105,179
+25,000
+31% +$60K
INGN icon
73
Inogen
INGN
$176M
$78.3K 0.02%
15,000
– –
SLRN
74
DELISTED
ACELYRIN
SLRN
$74.2K 0.02%
+7,300
New +$155K
LCTX icon
75
Lineage Cell Therapeutics
LCTX
$282M
– –
-140,000
Closed -$197K
1 2
3
4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
DBG
De Burlo Group Boston, Massachusetts $441M AUM 21.21% 1-Year Est. Return
SPT
Siemens Pension Trust Munich Germany, Germany $437M AUM 183.71% 1-Year Est. Return

DAFNA Capital Management's Q3 2023 Portfolio in Review

As of Q3 2023, DAFNA Capital Management held 83 positions worth $321M, down 12% from $366M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

DAFNA Capital Management's Q3 2023 filing shows 10 new, 22 increased, 13 reduced and 8 closed positions. Its largest new stake was Amylyx Pharmaceuticals: 122,547 shares worth $2.24M. The largest sale was IVERIC bio, Inc. Common Stock, an estimated $24.1M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 83% a quarter earlier.

  • DAFNA Capital Management's largest Q3 2023 buy was Amylyx Pharmaceuticals: 122,547 shares worth $2.24M.
  • DAFNA Capital Management added most to 2seventy bio in Q3 2023, an estimated $6.24M increase.
  • DAFNA Capital Management's biggest Q3 2023 reduction was Revolution Medicines, cutting an estimated $1.15M.
  • DAFNA Capital Management fully exited IVERIC bio, Inc. Common Stock in Q3 2023, selling an estimated $24.1M.
  • DAFNA Capital Management's ten largest holdings make up 51% of its $321M portfolio in Q3 2023.
  • DAFNA Capital Management opened 10 new positions and closed 8 in Q3 2023.
  • DAFNA Capital Management's portfolio value fell 12% quarter-over-quarter to $321M.

Based on DAFNA Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.